18F-FDG PET/CT引导姑息放疗对复发髓系肉瘤十余处病灶产生持久缓解
18F-Fluorodeoxyglucose PET/CT-Guided Palliative Radiotherapy Provides Durable Responses to Over a Dozen Sites of Disease in Relapsed Myeloid Sarcoma.
PubMed 文献 · Clin Nucl Med · 2020-01-01
本文报道一例72岁女性多灶性髓外髓系肉瘤(MS)患者,在两次复发过程中利用FDG PET/CT引导对13处病灶行姑息放疗,获得完全且持久的局部缓解且毒性轻微。该病例为目前报道中经FDG PET/CT引导放疗成功治疗的最大疾病负荷MS病例。
要点
- FDG PET/CT可用于髓系肉瘤分期与疗效评估。
- FDG PET/CT引导姑息放疗可对多灶复发MS实现持久局部控制。
- 该病例为FDG PET/CT引导放疗治疗MS的最大疾病负荷报道。
核心结论
- FDG PET/CT引导的姑息放疗可使多灶复发髓系肉瘤患者获得完全且持久的局部缓解,且毒性轻微。
研究设计与样本
- 本文为个案报道,对象为一名72岁女性多灶性髓外髓系肉瘤患者。
主要发现
- 患者在两次独立复发过程中经FDG PET/CT引导对13处病灶行姑息放疗,获得完全且持久的局部缓解,毒性轻微。
临床怎么用
- 对多灶性复发髓系肉瘤,可考虑以FDG PET/CT引导姑息放疗实现多病灶局部控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloid sarcoma (MS) is a rare entity, and FDG PET/CT is a useful tool for staging at diagnosis and response assessment. We present a case of a 72-year-old woman diagnosed with multifocal extramedullary MS, using FDG PET/CT to guide palliative radiotherapy to 13 sites of disease over 2 separate relapses with complete and durable local responses and minimal toxicity. This case represents the largest reported burden of disease in MS successfully treated with FDG PET/CT-guided radiotherapy.
来源:Clin Nucl Med,查看原文。版权归原作者所有。
引用
- Shuttleworth C, Wegner EA, Thompson SR, et al. 18F-Fluorodeoxyglucose PET/CT-Guided Palliative Radiotherapy Provides Durable Responses to Over a Dozen Sites of Disease in Relapsed Myeloid Sarcoma. Clin Nucl Med. 2020. PMID: 32804769. doi:10.1097/RLU.0000000000003238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。